GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

With PAS in place, the hospital expects to serve up to 24 mothers per hour for obstetrics-gynecology services and 10 adolescent patients per hour, improving patient flow and service delivery. To book ...

CMS is exploring a number of tech initiatives to make it easier for providers and patients to access data, including a national provider directory. Updated June 4, 9:30 a.m. ...

Insurance companies often refer patients to lists of providers who are unreachable, out of network or don’t accept new patients.

Other clinicians insisted that patients slow down — that, after a dramatic loss, they try to acclimate to their new bodies before requesting to die. Dr. Donna Stewart, a psychiatrist at Toronto ...

REZILIENT1 (ClinicalTrials.gov identifier: NCT04036682) is a phase I/II open-label trial enrolling patients with locally advanced or metastatic EGFR ex20ins-mutant NSCLC previously treated with ...

UChicago Medicine said it has alerted about 38,000 patients of the UCM Medical Group that they have been affected by a data breach. Latest U.S.

ORLANDO — Primary care providers can use a new clinical advisory guideline to nutritionally support patients who are using GLP-1 receptor agonists, according to experts.The joint advisory was ...

“The dosing of the first patient in our first Phase II trial of AL001 is another significant step forward in our goal to introduce a next-generation lithium treatment that offers enhanced safety ...

SINGAPORE: Instead of trying to "squeeze" patients, building long-term relationships is key to the business model of the healthcare firm that bid S$52,188 (US$40,500) in monthly rent for a unit in ...